報價延遲最少15分鐘:2025/06/01 05:21 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1602 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.37/-0.00
|
|
企業價值
2.35M
|
| 資產負債 |
|
每股賬面淨值
0.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 05:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailtyand sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine. |